O'Neill report on AMR calls for $2 billion fund from pharma

The pharma industry is being called on to provide a $2 billion fund to defeat antimicrobial resistance, in a new report released today.

The Commission on Antibiotic Resistance’s third report,  Securing New Drugs for Future Generations: The Pipeline of Antibiotics, by the Chair of the Commission, Jim O’Neill, previously chief economist at Goldman Sachs, paints a bleak picture of the global situation. The report, commissioned by the UK Prime Minister David Cameron last year, estimates the global economic cost of AMR by 2050 using studies based on high-level scenarios. It found that a continued rise in resistance by 2050 would lead to 10 million people dying every year and a reduction of 2% to 3.5% in Gross Domestic Product (GDP). It would cost the world up to $100 trillion.

Study results